Baidu
map

Nat Commun:郑州大学王立东团队揭示中国北方贲门癌可能与饮食有关

2021-11-18 “ E药世界”公众号 “ E药世界”公众号

该研究一反长期聚焦阐明细胞核染色质DNA与肿瘤发生关系研究的思路,发现位于细胞质内的染色质外DNA(ecDNA)与贲门癌关系密切。

河南、河北和山西三省交界的南太行山地区,特别是河南林州(原林县)是中国也是世界上食管癌和贲门癌发病率和死亡率最高的地区。

1959年,河南省政府组建以河南医学院牵头的,以沈琼教授、刘桂亭教授、裘宋良教授等为代表的食管癌防治医疗队深入林县开展多学科综合防治研究。从此揭开了郑州大学医科三代人、六十年河南食管癌高发现场防治的波澜壮阔的传承研究,三代人接力从细胞和组织、分子和基因等不同方面揭示食管癌和贲门癌变多阶段演进的分子机制,建立用于高危人群预警筛查和早期发现的分子分型及监测技术体系,取得了一系列原创性成果,并得到国内外学者的高度评价和赞誉,为开展食管癌和贲门癌三级预防(病因、癌前病变干预和复发转移等)提供了重要理论依据和技术支撑。

近日,郑州大学省部共建食管癌防治国家重点实验室、郑州大学第一附属医院王立东教授团队和瑞典乌普萨拉大学陈兴启教授团队合作,在 Nature 子刊 Nature Communications 上发表了题为:Focal amplifications are associated with chromothripsis events and diverse prognoses in gastric cardia denocarcinoma 的研究论文。

该研究一反长期聚焦阐明细胞核染色质DNA与肿瘤发生关系研究的思路,发现位于细胞质内的染色质外DNA(ecDNA)与贲门癌关系密切。

该研究发现,中国贲门癌患者中频繁出现局灶性扩增和染色质外DNA(ecDNA),还发现其中的局灶性扩增与染色体碎裂过程有关,这可能是由当地饮食习惯导致的累积DNA损伤诱导的。

该研究对比分析了贲门腺癌和贲门正常组织全基因组测序(WGS)和染色质外环状DNA测序(circle-seq)数据,鉴定出染色质外DNA(ecDNA)扩增子;证实1/3的局灶性扩增为染色体碎裂引起的;WGS中鉴定出大部分扩增子在ecDNA测序中得到验证;发现所有局灶性扩增片段仅发生在癌细胞中。

该研究还发现:贲门癌组织ecDNA中ERBB2基因的局灶性扩增和蛋白表达之间存在正相关;对1688例贲门癌组织ERBB2蛋白表达和生存关系分析发现,在生存期大于2年的贲门癌患者中,ERBB2蛋白高表达患者组生存期明显优于阴性表达组;发现其中28例贲门腺癌组织ecDNA基因组的局灶性扩增的频率(78%)与食管鳞癌非常相似(80%),但与远端胃癌明显不同(50%)。

王立东教授,现任郑州大学省部共建食管癌防治国家重点实验室主任。王教授1985年就职于郑州大学以来,一直长期从事食管癌防治研究,带领研究团队27年间走访12万个食管癌高发区自然村,建立了50万例食管癌和贲门癌临床诊疗、病理和44年随访信息数据库和生物样品库研究队列、5.4万例高发区无症状居民33年内镜活检随访队列;发现15个食管癌和贲门癌易感基因;揭示环境-遗传-基因互作影响食管癌发生的分子机理;创建了食管癌高危人群预警和早期发现液体活检关键技术指标和监测体系并在高发区推广应用,取得显着效果。在 Nature Genetics 、Gut、PNAS、Cancer Discovery 等期刊发表多篇研究论文。

陈兴启教授,博士毕业于卡罗林斯卡医学院,在斯坦福大学完成博士后研究工作。目前陈教授工作于瑞典乌普萨拉大学,主要从事染色质的组织包装和基因表达调控研究,在Nature、Nature Methods、Nature Communications、Genome Research、Molecular Cell、Nucleic Acids Research等期刊发表多篇研究论文。

郑州大学第一附属医院赵学科博士、宋昕博士和乌普萨拉大学邢鹏伟博士为共同第一作者,王立东教授和乌普萨拉大学陈兴启教授为共同通讯作者。

 

原始出处:

Zhao, XK., Xing, P., Song, X. et al. Focal amplifications are associated with chromothripsis events and diverse prognoses in gastric cardia adenocarcinoma. Nat Commun 12, 6489 (2021). https://doi.org/10.1038/s41467-021-26745-3.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1885506, encodeId=676c188550626, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 29 10:25:46 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088115, encodeId=57e62088115d1, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Oct 26 08:25:46 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813404, encodeId=136418134045a, content=<a href='/topic/show?id=6604924e4a6' target=_blank style='color:#2F92EE;'>#贲门癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92474, encryptionId=6604924e4a6, topicName=贲门癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Mon Aug 15 05:25:46 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747145, encodeId=fe151e471457d, content=<a href='/topic/show?id=d9d192468dd' target=_blank style='color:#2F92EE;'>#贲门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92468, encryptionId=d9d192468dd, topicName=贲门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d50035925343, createdName=gostraight, createdTime=Mon Aug 22 20:25:46 CST 2022, time=2022-08-22, status=1, ipAttribution=)]
    2022-05-29 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1885506, encodeId=676c188550626, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 29 10:25:46 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088115, encodeId=57e62088115d1, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Oct 26 08:25:46 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813404, encodeId=136418134045a, content=<a href='/topic/show?id=6604924e4a6' target=_blank style='color:#2F92EE;'>#贲门癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92474, encryptionId=6604924e4a6, topicName=贲门癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Mon Aug 15 05:25:46 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747145, encodeId=fe151e471457d, content=<a href='/topic/show?id=d9d192468dd' target=_blank style='color:#2F92EE;'>#贲门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92468, encryptionId=d9d192468dd, topicName=贲门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d50035925343, createdName=gostraight, createdTime=Mon Aug 22 20:25:46 CST 2022, time=2022-08-22, status=1, ipAttribution=)]
    2022-10-26 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1885506, encodeId=676c188550626, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 29 10:25:46 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088115, encodeId=57e62088115d1, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Oct 26 08:25:46 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813404, encodeId=136418134045a, content=<a href='/topic/show?id=6604924e4a6' target=_blank style='color:#2F92EE;'>#贲门癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92474, encryptionId=6604924e4a6, topicName=贲门癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Mon Aug 15 05:25:46 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747145, encodeId=fe151e471457d, content=<a href='/topic/show?id=d9d192468dd' target=_blank style='color:#2F92EE;'>#贲门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92468, encryptionId=d9d192468dd, topicName=贲门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d50035925343, createdName=gostraight, createdTime=Mon Aug 22 20:25:46 CST 2022, time=2022-08-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1885506, encodeId=676c188550626, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 29 10:25:46 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088115, encodeId=57e62088115d1, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Oct 26 08:25:46 CST 2022, time=2022-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813404, encodeId=136418134045a, content=<a href='/topic/show?id=6604924e4a6' target=_blank style='color:#2F92EE;'>#贲门癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92474, encryptionId=6604924e4a6, topicName=贲门癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca282500032, createdName=1249857fm32暂无昵称, createdTime=Mon Aug 15 05:25:46 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747145, encodeId=fe151e471457d, content=<a href='/topic/show?id=d9d192468dd' target=_blank style='color:#2F92EE;'>#贲门#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92468, encryptionId=d9d192468dd, topicName=贲门)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d50035925343, createdName=gostraight, createdTime=Mon Aug 22 20:25:46 CST 2022, time=2022-08-22, status=1, ipAttribution=)]
    2022-08-22 gostraight
Baidu
map
Baidu
map
Baidu
map